CMcrpred

CMcrpred predicts risk in cutaneous melanoma patients by integrating clinico-pathological features and gene-expression profiles to improve prognostication.

Key Features:

• Integration of Clinico-Pathological and Gene-Expression Data: Combines clinico-pathological features such as Breslow thickness and AJCC tumor staging with gene-expression profiles associated with cancer-related pathways.
• Biomarker Development: Utilizes biomarkers derived from clinical data and gene-expression profiles, with emphasis on pathways including apoptosis and Notch signaling, for prognostic assessment.
• Gene-Expression Based Models: Gene-expression models show hazard ratios (HR) up to 2.52 for the apoptotic pathway and up to 2.57 when apoptotic genes are combined with Notch pathway genes.
• Clinico-Pathological Feature Models: Individual clinical features, for example Breslow thickness, produced a maximum HR of 2.45.
• Combined Models: Models integrating clinical variables and gene-expression data achieved a maximum HR of 3.19.
• Ensemble Method for Clinical Variables: An ensemble method using only clinico-pathological features produced a maximum HR of 6.40, exceeding performance of gene-expression models and AJCC staging.

Scientific Applications:

• Melanoma prognostication and risk stratification: Provides quantitative risk estimates to support prognostic assessment in cutaneous melanoma patients.
• Biomarker evaluation and pathway analysis: Supports identification and evaluation of prognostic biomarkers and the involvement of pathways such as apoptosis and Notch signaling in melanoma progression.

Methodology:

Analyzing gene-expression profiles related to key cancer pathways, evaluating clinico-pathological features for prognostic value, creating models that integrate both data types, and implementing an ensemble method focused solely on clinical variables.